Lipocine (LPCN) Posts Quarterly Earnings Results, Beats Estimates By $0.12 EPS

Lipocine (NASDAQ:LPCN) posted its quarterly earnings data on Wednesday. The specialty pharmaceutical company reported ($0.12) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.24) by $0.12, MarketWatch Earnings reports.

Shares of NASDAQ:LPCN traded up $0.14 during trading hours on Thursday, hitting $1.63. 408,400 shares of the company’s stock traded hands, compared to its average volume of 321,209. Lipocine has a 52 week low of $1.03 and a 52 week high of $4.01. The company has a current ratio of 8.89, a quick ratio of 8.89 and a debt-to-equity ratio of 0.62. The firm has a market cap of $31.90 million, a price-to-earnings ratio of -1.55 and a beta of 0.41.

Separately, Canaccord Genuity restated a “hold” rating and set a $1.50 price objective on shares of Lipocine in a research report on Friday, August 10th. Two research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $6.38.

TRADEMARK VIOLATION NOTICE: This report was originally reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this report on another domain, it was illegally stolen and republished in violation of US & international trademark and copyright legislation. The correct version of this report can be viewed at https://sportsperspectives.com/2018/11/08/lipocine-lpcn-posts-quarterly-earnings-results-beats-estimates-by-0-12-eps.html.

Lipocine Company Profile

Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics, facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.

Featured Story: Conference Calls

Earnings History for Lipocine (NASDAQ:LPCN)

Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply